SCHEMBL4327020

SCHEMBL4327020

Cc1ccsc1C(=O)Nc1cc(F)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 3/20 0.58
▸ AURKB Q96GD4 2/20 0.58
▸ NPC1 O15118 4/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ MAPT P10636 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ KDR P35968 4/20 0.40
▸ HPGD P15428 1/20 0.39
▸ CSF1R P07333 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ KIT P10721 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ FGFR1 P11362 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4327023 1.00 AURKA (0.58) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4313356 0.89 AURKA (0.56) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4313350 0.89 AURKA (0.56) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4314044 0.89 AURKA (0.57) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4314213 0.89 AURKA (0.57) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4314052 0.89 AURKA (0.57) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4314217 0.89 AURKA (0.57) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4313957 0.88 AURKA (0.66) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL31824 0.88 AURKA (0.66) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4321146 0.88 AURKA (0.63) AURKAAURKBNPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885NPC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback